A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML

The response rate of non-M3 AML to all trans retinoic acid (ATRA) has been limited. Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA. We therefore per...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Welch, John S., Niu, Haixia, Uy, Geoffrey L., Westervelt, Peter, Abboud, Camille N., Vij, Ravi, Stockerl-Goldstein, Keith E., Jacoby, Meagan, Pusic, Iskra, Schroeder, Mark A., Dipersio, John F., Cashen, Amanda F.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4108244/
https://ncbi.nlm.nih.gov/pubmed/24723466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23735
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky